-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Azacitidine + Cedazuridine) in Refractory Anemia With Excess Blasts
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Azacitidine + Cedazuridine) in Refractory Anemia With Excess Blasts report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Azacitidine + Cedazuridine) in Refractory Anemia...
-
Product Insights
Anshan Blast Furnace Gas Combined Cycle Power Plant
Anshan Blast Furnace Gas Combined Cycle Power Plant is a thermal project located in Liaoning, China. The project is owned by Anshan Iron and Steel Group Co Ltd. The project came online in 2007. Empower your strategies with our Anshan Blast Furnace Gas Combined Cycle Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azacitidine in Pancreatic Ductal Adenocarcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Pancreatic Ductal Adenocarcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azacitidine in Pancreatic Ductal Adenocarcinoma Drug Details: Azacitidine (Vidaza, Azafuridine, Celazadine)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azacitidine in Peripheral T-Cell Lymphomas (PTCL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Peripheral T-Cell Lymphomas (PTCL) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azacitidine in Peripheral T-Cell Lymphomas (PTCL) Drug Details: Azacitidine (Vidaza,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azacitidine in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azacitidine in Diffuse Large B-Cell Lymphoma Drug Details: Azacitidine (Vidaza,...
-
Company Insights
Innovation and Patenting activity of Guangdong Hongda Blasting Co Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Guangdong Hongda Blasting Co Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Azacitidine in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Azacitidine in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Azacitidine in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ponatinib Hydrochloride in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ponatinib Hydrochloride in T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ponatinib Hydrochloride in T-Cell Acute...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ponatinib Hydrochloride in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ponatinib Hydrochloride in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ponatinib Hydrochloride in Acute Myelocytic Leukemia...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Iodine I 131 Apamistamab in Refractory Anemia With Excess Blasts
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Iodine I 131 Apamistamab in Refractory Anemia With Excess Blasts report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Iodine I 131 Apamistamab in Refractory Anemia...